Exome Asset Management LLC Decreases Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Exome Asset Management LLC reduced its holdings in Structure Therapeutics by 32.3%, selling 49,021 shares, and now holds approximately 1.5% of the company.
• Structure Therapeutics reported an earnings miss with a loss of ($0.36) EPS, compared to the consensus estimate of ($0.28), and analysts predict an EPS of -0.82 for the current year.
• Despite Exome's sell-off, other funds have increased their stakes significantly, with GAMMA Investing LLC boosting its ownership by 663.8% in the first quarter.

Exome Asset Management LLC lowered its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 32.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 102,944 shares of the company's stock after selling 49,021 shares during the period. Structure Therapeutics makes up approximately 1.5% of Exome Asset Management LLC's portfolio, making the stock its 29th largest position. Exome Asset Management LLC owned about 0.18% of Structure Therapeutics worth $1,782,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vestal Point Capital LP increased its holdings in shares of Structure Therapeutics by 3.7% during the 1st quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock worth $30,967,000 after buying an additional 63,990 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Structure Therapeutics by 3,326.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company's stock worth $949,000 after buying an additional 53,216 shares during the last quarter. Point72 Europe London LLP increased its holdings in shares of Structure Therapeutics by 188.7% during the 1st quarter. Point72 Europe London LLP now owns 90,697 shares of the company's stock worth $1,570,000 after buying an additional 59,277 shares during the last quarter. DAFNA Capital Management LLC increased its holdings in shares of Structure Therapeutics by 66.2% during the 1st quarter. DAFNA Capital Management LLC now owns 59,000 shares of the company's stock worth $1,021,000 after buying an additional 23,500 shares during the last quarter. Finally, Trexquant Investment LP increased its holdings in shares of Structure Therapeutics by 127.6% during the 1st quarter. Trexquant Investment LP now owns 120,340 shares of the company's stock worth $2,083,000 after buying an additional 67,464 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Trading Up 0.1%

Structure Therapeutics stock traded up $0.03 during trading on Friday, hitting $20.91. The company had a trading volume of 1,466,150 shares, compared to its average volume of 1,068,199. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $13.22 and a 1-year high of $45.37. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -19.91 and a beta of -1.89. The company's 50 day simple moving average is $18.90 and its 200-day simple moving average is $20.66.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

GPCR has been the subject of a number of recent analyst reports. HC Wainwright cut their price target on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a report on Thursday, August 7th. JMP Securities dropped their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a report on Thursday, August 7th. Lifesci Capital upgraded shares of Structure Therapeutics to a "strong-buy" rating in a report on Monday, September 8th. Guggenheim dropped their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.